Xilio Therapeutics develops masked immunotherapy treatments that activate inside tumors to treat cancer. It last closed at $7.54 on Nov 17, down 2.08% on the day.
Only 1 firm rated XLO in the past 90 days, not enough for a consensus
Average 12-month target
$16.00
▲ 112.2% upside
Based on 1 analyst who set a price target on XLO in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $7.54.
Low $16.00Avg $16.00High $16.00
Blue marker: last close $7.54
Highest target$16.00
Average target$16.00
Lowest target$16.00
Latest rating changes
Raymond JamesInitiated
Oct 21Buy$16
Date
Firm
Action
Rating
Price target
Oct 21
Raymond James
Initiated
Buy
$16
Loading…
Technical Analysis
XLO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 8% below its 20 day and 15% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Jun 5) at $7.53, and the nearest resistance the Pivot R1 at $7.87.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$11.3052 week high+49.9%
$8.86100 day average+17.5%
$8.6450 day average+14.6%
$8.48200 day average+12.5%
$8.33Swing high (Jun 8)+10.5%
$8.1620 day average+8.2%
$7.87Pivot R1+4.4%
$7.54Last close
$7.53Swing low (Jun 5)−0.1%
$7.51Pivot−0.4%
$7.17Pivot S1−4.9%
$6.4752 week low−14.2%
Indicators
RSI (14)
36.01
Weak, oversold below 30
Neutral
MACD
-0.18
Below its signal line
Bearish
Stochastic
36.1
Middle of its range
Neutral
ADX (14)
27.4
Trending down
Williams %R
-74.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
-117.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−13.1%
Change over 10 sessions
Bearish
ATR (14)
$0.63
Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityLow, 13.2%/day
Key levels
$11.3052 week high+49.9%
$8.86100 day average+17.5%
$8.6450 day average+14.6%
$8.48200 day average+12.5%
$8.33Swing high (Jun 8)+10.5%
$8.1620 day average+8.2%
$7.87Pivot R1+4.4%
$7.54Last close
$7.53Swing low (Jun 5)−0.1%
$7.51Pivot−0.4%
$7.17Pivot S1−4.9%
$6.4752 week low−14.2%
Indicators
RSI (14)
38.41
Weak, oversold below 30
Neutral
MACD
-0.21
Below its signal line
Bearish
Stochastic
36.0
Middle of its range
Neutral
ADX (14)
14.7
No clear trend
Williams %R
-82.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-189.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.6%
Change over 10 sessions
Bearish
ATR (14)
$1.00
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XLO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how XLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow XLO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XLO is in one of them and how their past XLO trades turned out.
Xilio Therapeutics is a biotechnology company that discovers and develops cancer immunotherapies designed to stay inactive until they reach tumors. Enzymes found in tumors remove the mask, which aims to limit activity in healthy tissue. Its pipeline includes a masked IL-2 fusion protein and masked T cell engagers, and it has partnerships with AbbVie and Gilead. The company is based in Waltham, Massachusetts, and is developing its treatments for patients with cancer.